Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
The syndromes of microangiopathic hemolytic anemia, thrombocytopenia, and variable signs of organ impairment, due to platelet aggregation in the microcirculation.
Biomarker and diagnostic research for thrombotic microangiopathy has been reported in the published literature.
8 clinical trials registered, 6 recruiting. Interventions under study include drug therapy, other interventions, and biologic therapy. Pipeline includes 1 PHASE4, 1 PHASE3, 2 PHASE2. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT04543591](https://clinicaltrials.gov/study/NCT04543591) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 8:41 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant |
PHASE3 |
Alexion Pharmaceuticals, Inc. |
UNKNOWN |
[NCT06759961](https://clinicaltrials.gov/study/NCT06759961) | Post-transplant Thrombotic Microangiopathy: Evaluation of Outcomes at the Bologna Kidney Transplant Centre | — | IRCCS Azienda Ospedaliero-Universitaria di Bologna | RECRUITING |
[NCT05743400](https://clinicaltrials.gov/study/NCT05743400) | Thymoglobulin® Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell Transplantation | PHASE4 | Hospices Civils de Lyon | RECRUITING |
[NCT07279610](https://clinicaltrials.gov/study/NCT07279610) | N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy | PHASE2 | The First Affiliated Hospital of Soochow University | ACTIVE_NOT_RECRUITING |
[NCT07347990](https://clinicaltrials.gov/study/NCT07347990) | Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic Microangiopathy | NA | First Affiliated Hospital of Zhejiang University | RECRUITING |
255 publications have been identified in PubMed for thrombotic microangiopathy. Research spans Case Report / Case Series (38%), Review / Meta-Analysis (22%), and Epidemiology / Natural History (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 96 | 38% |
Research summaries | 55 | 22% |
Disease patterns and progression | 33 | 13% |
Clinical study results | 26 | 10% |
Laboratory research | 17 | 7% |
Testing and diagnosis research | 14 | 5% |
New treatment approaches | 8 | 3% |
Other research | 6 | 2% |
Kodera T (2026). [PMID: 41615001](https://pubmed.ncbi.nlm.nih.gov/41615001/). *Mod Rheumatol Case Rep*. [Case Report / Case Series]
Panda S (2026). [PMID: 41519809](https://pubmed.ncbi.nlm.nih.gov/41519809/). *J Med Case Rep*. [Review / Meta-Analysis]
Smith MA (2026). [PMID: 41248753](https://pubmed.ncbi.nlm.nih.gov/41248753/). *Transplant Cell Ther*. [Diagnostic / Biomarker]
Drapeau L (2026). [PMID: 40915575](https://pubmed.ncbi.nlm.nih.gov/40915575/). *Am J Transplant*. [Diagnostic / Biomarker]
Han J (2026). [PMID: 41907348](https://pubmed.ncbi.nlm.nih.gov/41907348/). *Obstet Med*. [Case Report / Case Series]
Li Q (2026). [PMID: 42161885](https://pubmed.ncbi.nlm.nih.gov/42161885/). *Ren Fail*. [Epidemiology / Natural History]
Deshpande A (2026). [PMID: 42231808](https://pubmed.ncbi.nlm.nih.gov/42231808/). *Int J Surg Pathol*. [Case Report / Case Series]
Story CM (2026). [PMID: 41784357](https://pubmed.ncbi.nlm.nih.gov/41784357/). *Expert Rev Hematol*. [Review / Meta-Analysis]
Frost EL (2026). [PMID: 41725146](https://pubmed.ncbi.nlm.nih.gov/41725146/). *Pediatr Blood Cancer*. [Diagnostic / Biomarker]
Fargeat M (2026). [PMID: 41609702](https://pubmed.ncbi.nlm.nih.gov/41609702/). *Revue medicale suisse*. [Review / Meta-Analysis]
AI-curated news mentioning thrombotic microangiopathy
Updated Sep 4, 2026
A recent study highlights the occurrence of collapsing glomerulopathy and thrombotic microangiopathy following chimeric antigen receptor T cell therapy. This research adds to the understanding of potential complications associated with CAR T-cell treatments.
A case report details the multimodal management of anti-GBM disease complicated by secondary complement-mediated thrombotic microangiopathy in a patient who could not tolerate plasma exchange. This study highlights alternative treatment strategies for complex cases.
A new case series published on renal-limited thrombotic microangiopathy in infants provides insights into this rare condition. The findings may enhance understanding and management of the disease in pediatric populations.